The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation

AIDS

Volumn 29, Issue 4, 2015, Pages 463-471

  Wada, Nikolas Itaru ^a   Jacobson, Lisa P ^a   Margolick, Joseph B ^a   Breen, Elizabeth Crabb ^b   Macatangay, Bernard ^c   Penugonda, Sudhir ^d   Martínez Maza, Otoniel ^b   Bream, Jay H ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

AIDS; antiretroviral therapy; biological markers; inflammation; male; prospective studies

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; B CELL ACTIVATING FACTOR; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12P70; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 4; PROTEIN; SGP130 PROTEIN; SOLUBLE CD14 ANTIGEN; SOLUBLE CD27 ANTIGEN; STNFR2 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS RNA; BETA CHEMOKINE; INTERLEUKIN 6; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; INFLAMMATION; INTERVENTION STUDY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NORMAL VALUE; PLASMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SERUM; TREATMENT DURATION; VIRUS LOAD; BLOOD; CD4 LYMPHOCYTE COUNT; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOMARKERS; C-REACTIVE PROTEIN; CD4 LYMPHOCYTE COUNT; CHEMOKINES, CC; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFLAMMATION; INTERLEUKIN-6; LYMPHOCYTE ACTIVATION; MALE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84922284220     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000545     Document Type: Article

References (31)

1. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 1997; 315:1194-1199
2. Detels R, Munoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998; 280:1497-1503
3. Wada N, Jacobson L, Cohen M, French AL, Phair JP, Munoz A. Cause-specific life expectancies after age 35 for HIV-infected and HIV-negative individuals followed simultaneously in longterm cohort studies: 1984-2008. Am J Epidemiol 2013; 177:116-125
4. LeDerman MM, FunDerburg NT, Sekaly RP, Klatt NR, Hunt PW. Residual immune dysregulation syndrome in treated HIV infection. Adv Immunol 2013; 119:51-83
5. Plaeger SF, Collins BS, Musib R, Deeks SG, Read S, Embry A. Immune activation in the pathogenesis of treated chronic HIV disease: a workshop summary. AIDS Res Hum Retroviruses 2012; 28:469-477
6. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, et al. T cell activation is associated with lower CD4R T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187:1534-1543
7. LeDerman MM, Calabrese L, FunDerburg NT, Clagett B, Medvik K, Bonilla H, et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis 2011; 204:1217-1226
8. Hazenberg MD, Otto SA, Van Benthem BH, Roos MT, Coutinho RA, Lange JM, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003; 17:1881-1888
9. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-1371
10. Hatano H. Immune activation and HIV persistence: consiDerations for novel therapeutic interventions. Curr Opin HIV AIDS 2013; 8:211-216
11. RegidorDL, Detels R, Breen EC, Widney DP, Jacobson LP, Palella FJ Jr, et al. Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation. AIDS 2011; 25:303-314
12. Widney DP, Breen EC, Boscardin WJ, Kitchen SG, Alcantar JM, Smith JB, et al. Serum levels of the homeostatic B cell chemokine, CXCL13, are elevated during HIV infection. J Interferon Cytokine Res 2005; 25:702-706
13. Kaplan RC, Landay AL, Hodis HN, Gange SJ, Norris PJ, Young M, et al. Potential cardiovascular disease risk markers among HIV-infected women initiating antiretroviral treatment. J Acquir Immune Deficiency Syndr 2012; 60:359-368
14. Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, La Rosa A, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201:1788-1795
15. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR Jr. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol 1987; 126:310-318
16. Hultin LE, Menendez FA, Hultin PM, Jamieson BD, OGorman MR, Borowski L, et al. Assessing immunophenotyping performance: proficiency-validation for adopting improved flow cytometry methods. Cytometry B Clin Cytom 2007; 72:249-255
17. SchneiDer MF, Margolick JB, Jacobson LP, Reddy S, Martinez-Maza O, Munoz A. Improved estimation of the distribution of suppressed plasma HIV-1 RNA in men receiving effective antiretroviral therapy. J Acquir Immune Defic Syndr 2012; 59:389-392
18. Cox C, Chu H, SchneiDer MF, Munoz A. Parametric survival analysis and taxonomy of hazard functions for the generalized gamma distribution. Stat Med 2007; 26:4352-4374
19. Dunn OJ. Multiple comparisons among means. J Am Stat Assoc 1961; 50:1096-1121
20. Bosch RJ, Zhang X, Sandler NG. Study design issues in evaluating immune biomarkers. Curr Opin HIV AIDS 2013; 8:147-154
21. Crotty S. Follicular helper CD4 T cells (TFH). Ann Rev Immunol 2011; 29:621-663
22. Kumar A, Abbas W, Herbein G. TNF and TNF receptor superfamily members in HIV infection: new cellular targets for therapy? Mediators Inflamm 2013; 2013:484378
23. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203:780-790
24. Cassol E, Cassetta L, Rizzi C, Alfano M, Poli G. M1 and M2a polarization of human monocyte-Derived macrophages inhibits HIV-1 replication by distinct mechanisms. J Immunol 2009; 182:6237-6246
25. Herbein G, Varin A. The macrophage in HIV-1 infection: from activation to deactivation? Retrovirology 2010; 7:33
26. Zhang W, He J, Zhang F, Huang C, Wu Y, Han Y, et al. Prognostic role of C-reactive protein and interleukin-6 in dialysis patients: a systematic review and meta-analysis. J Nephrol 2013; 26:243-253
27. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336:973-979
28. Swede H, Hajduk AM, Sharma J, Rawal S, Rasool H, Vella AT, et al. Baseline serum C-reactive protein and death from colorectal cancer in the NHANES III cohort. Int J Cancer 2014; 134:1862-1870
29. Klatt NR, Chomont N, Douek DC, Deeks SG. Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol Rev 2013; 254:326-342
30. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc Series B 1995; 57:289-300
31. Kamat A, Misra V, Cassol E, Ancuta P, Yan Z, Li C, et al. A plasma biomarker signature of immune activation in HIV patients on antiretroviral therapy. PLoS One 2012; 7:e30881